nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.10.2008 | Preclinical Study

High frequency of HIF-1α overexpression in BRCA1 related breast cancer

verfasst von: Petra van der Groep, Alwin Bouter, Fred H. Menko, Elsken van der Wall, Paul J. van Diest

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Hypoxia is a hallmark of cancer. Hypoxia inducible factor-1α (HIF-1α) is the key regulator of the hypoxia response. HIF-1α is overexpressed during sporadic breast carcinogenesis and correlated with poor prognosis. Little is known on the role of HIF-1α in hereditary breast carcinogenesis. A recent study suggests a role for BRCA1 in HIF-1α regulation. We therefore examined the expression of HIF-1α in BRCA1 related breast cancers. By immunohistochemistry we studied expression of HIF-1α and some of its downstream targets in 30 hereditary invasive breast cancers in comparison with 200 sporadic controls. HIF-1α overexpression was significantly more frequent in BRCA1 related breast cancers (27/30, 90%) than in sporadic controls (88/200, 44%) (P < 0.0001). 19/30 (63%) of BRCA1 tumors showed perinecrotic (hypoxia induced) and 8/30 (27%) a diffuse HIF-1α overexpression pattern, the latter more likely related to genetic alterations in oncogenes and tumor suppressor genes. In contrast, sporadic breast cancer HIF-1 expressing tumors showed an inverse ratio of perinecrotic/diffuse expression (31 vs. 69%, P = 0.0002). Glut-1 and CAIX, downstream HIF1 targets, were expressed in 27/30 (90%) and 15/21 (71%) of hereditary cases versus 54/183 (29%) and 24/183 (13%) in sporadic cases. p300 levels, necessary for HIF-1 downstream activation, were significantly higher in hereditary cases (20/21, 95%) compared to sporadic cases (91/183, 50%, P = 0.0001). In conclusion, in BRCA1 germline mutation related breast cancer, functional HIF-1α overexpression is seen at a much higher frequency than in sporadic breast cancer, mostly hypoxia induced. This points to an important role of hypoxia and its key regulator HIF-1α in hereditary breast carcinogenesis.

Jonsson G, Naylor TL, Vallon-Christersson J et al (2005) Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 65:7612–7621PubMed

van Beers EH, van Welsem T, Wessels LFA, Li Y, Oldenburg RA, Devilee P, Cornelisse CJ, Verhoef S, Hogervorst FBL, van’t Veer LJ, Nederlof PM (2005) Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 65:822–827PubMed

Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kaffioniemi P (1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57(7):1222–1227PubMed

Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, Paz MF, Honrado E, Rodríguez R, Urioste M, Valle L, Díez O, Cigudosa JC, Dopazo J, Esteller M, Benitez J (2005) A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res 11:1146–1153PubMed

Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, Ach R, Loman N, Olsson H, Meltzer P, Borg A, Trent J (2003) Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 100(5):2532–2537PubMedCrossRef

Wessels LF, van Welsem T, Hart AA, van’t Veer LJ, Reinders MJ, Nederlof PM (2002) Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 62:7110–7117PubMed

Armes JE, Venter DJ (2002) The pathology of inherited breast cancer. Pathology 34:309–314PubMedCrossRef

Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318PubMedCrossRef

Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT (1996) Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77(4):697–709PubMedCrossRef

10.

Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases (1997) Breast cancer linkage consortium. Lancet 349(9064):1505–1510PubMedCrossRef

11.

Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA (2004) The prognostic implication of the basal-like (Cyclin E^high/P27^low/p53⁺/glomeruloid-microvascular-proliferation⁺) phenotype of BRCA1-related breast cancer. Cancer Res 64:830–835PubMedCrossRef

12.

Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salmon A, Jacquernier J, Birnbaum D, Sobol H (1996) Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56(3):471–474PubMed

13.

Chappuis PO, Nethercot V, Foulkes WD (2000) Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18:287–295PubMedCrossRef

14.

Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD (2000) Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 18:4045–4052PubMed

15.

Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD (2001) TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61:4092–4097PubMed

16.

Straume O, Chappuis PO, Salvesen HB, Halvorsen OJ, Haukaas SA, Goffin JR, Begin LR, Foulkes WD, Akslen LA (2002) Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res 62:6808–6811PubMed

17.

Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423PubMedCrossRef

18.

Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelialphenotype in breast cancer. J Natl Cancer Inst 95:1482–1485PubMed

19.

Van der Groep P, Bouter A, van der Zanden R, Menko FH, Buerger H, Verheijen RH, van der Wall E, van Diest PJ (2004) Re: germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96(9):712–713PubMed

20.

Van der Groep P, Bouter A, van der Zanden R, Siccema I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ (2006) Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 59(6):611–617PubMedCrossRef

21.

Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF (2005) Breast cancer linkage consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11(14):5175–5180PubMedCrossRef

22.

Vaupel P, Thews O, Hoeckel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243–259PubMedCrossRef

23.

Salceda S, Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272:22642–22647PubMedCrossRef

24.

Huang LE, Gu J, Schau M, Bunn HF (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O₂-dependert degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci 95:7987–7992PubMedCrossRef

25.

Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo synthesis binds to the human erythropoeitin gene enhancer at a site required for transcriptational activation. Mol Cell Biol 12:5447–5454PubMed

26.

Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E (2003) Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast cancer. Cancer 97:1573–1581PubMedCrossRef

27.

Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93:309–314PubMedCrossRef

28.

Horrée N, Van Diest PJ, Van der Groep P, Sie-Go DMDS, Heintz APM (2007) Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol 29:219–227PubMed

29.

Bos R, van der Hoeven JJM, van der Wall E, van der Groep P, van Diest PJ, Comans EFI, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CFM (2002) Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379–387PubMedCrossRef

30.

Bos R, Van Diest PJ, van der Groep P, Greijer AE, Hermsen MAJA, Heijnen I, Meijer GA, Baak JPA, Pinedo HM, van der Wall E, Shvarts A (2003) Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene 22:8948–8951PubMedCrossRef

31.

Bos R, van Diest PJ, van der Groep P, Shvarts A, Greijer AE, van der Wall E (2004) Expression of hypoxia-inducible factor-1a and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res 6:R450–R459PubMedCrossRef

32.

Bos R, Van Diest PJ, De Jong JS, Van der Groep P, Van der Valk P, Van der Wall E (2005) Hypoxia-inducible factor-1a is associated with angiogenesis and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46:31–36PubMedCrossRef

33.

Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aardbodem Y, van Tinteren H, van Diest PJ, van der Wall E (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer. J Clin Pathol 58(2):172–177PubMedCrossRef

34.

Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouysségur J, Berra E (2007) HIF-1α and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 120:1451–1458PubMedCrossRef

35.

Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, Cho CH, Isaacs JS, Bae I (2006) BRCA1 plays a role in the hypoxic response by regulating HIF-1α stability and by modulating Vascular endothelial growth factor expression. J Biol Chem 281(19):13047–13056PubMedCrossRef

36.

van Diest PJ (2002) No consent should be needed for using leftover body material for scientific purposes. BMJ 325:648–651PubMedCrossRef

37.

van der Groep P, Bouter A, van der Zanden R et al (2004) Re: germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96:712–713PubMed

38.

Van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, Kurver PH, Bellot SM, Fijnheer J, van Gorp LH, Kwee WS et al (1992) Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the multicenter morphometric mammary carcinoma project. Hum Pathol 23:603–607PubMedCrossRef

39.

Laughner E, Taghari P, Chiles K, Mahon PC, Semenza GL (2001) Her2(neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1 mediated vascular endothelial growth factor expression. Mol Cell Biol 21(12):3995–4004PubMedCrossRef

40.

Vleugel MM, Greijer AE, van der Wall E, van Diest PJ (2005) Mutation analysis of the HIF-1α oxygen dependent degradation domain in invasive breast cancer. Cancer Genet Cytogenet 163(2):168–172PubMedCrossRef

41.

Vleugel MM, Bos R, Buerger H, van der Groep P, Saramäki OR, Visakorpi T, van der Wall E, van Diest PJ (2004) No amplifications of hypoxia-inducible factor-1α gene in invasive breast cancer: a tissue microarray study. Cell Oncol 26(5–6):347–351PubMed

42.

Van Diest PJ, van der Groep P, van der Wall E (2006) EGFR expression predicts BRCA1 status in patients with breast cancer. Clin Cancer Res 12(2):670PubMedCrossRef

43.

Peng XH, Kama P, Cao Z, Jiang BH, Zhou M, Yang L (2006) Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by upregulating survivin gene expression. J Biol Chem 281(36):25903–25914PubMedCrossRef

44.

Vleugel MM, Shvarts D, van der Wall E, van Diest PJ (2006) p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. Hum Pathol 37(8):1085–1092PubMedCrossRef

45.

Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogensis and therapeutics. Cancer Res 60:1541–1545PubMed

46.

Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8(1):258PubMedCrossRef

Titel: High frequency of HIF-1α overexpression in BRCA1 related breast cancer
verfasst von: Petra van der Groep
Alwin Bouter
Fred H. Menko
Elsken van der Wall
Paul J. van Diest
Publikationsdatum: 01.10.2008
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9817-z

Springer Medizin

High frequency of HIF-1α overexpression in BRCA1 related breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Oncological and aesthetic considerations of skin-sparing mastectomy

Genetic polymorphisms of XRCC1 (codon 399) and susceptibility to breast cancer in Iranian women, a case–control study

Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast

αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer

BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer

A polymorphism in the G protein β3-subunit gene is associated with bone metastasis risk in breast cancer patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie